ArticleBMC psychiatry2026
The predictive value of niacin skin flushing response and inflammatory factors for the antidepressant efficacy.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveIndividual variations in depressive disorder (DD) treatment responses highlight the need for early efficacy prediction to optimize regimens. The niacin skin flushing response (NSFR) is a potential DD biomarker, and elevated inflammatory cytokines are linked to DD. This study explored the association between blunted NSFR and DD symptom severity, and evaluated the predictive value of NSFR and inflammatory cytokines for early antidepressant efficacy.
methodsFifty DD patients were grouped as responders (≥ 50% Hamilton Depression Rating Scale reduction at week 2) or non-responders. Intergroup differences in NSFR index and inflammatory cytokines (Phospholipase A2 [PLA2], Cyclooxygenase-2 [COX-2]) were compared. Spearman’s correlation, binary logistic regression, and receiver operating characteristic (ROC) curves analyzed associations and predictive performance.
results(1) Baseline NSFR index was significantly negatively correlated with baseline HAMD score (r = -0.736, p < 0.001), indicating that the degree of NSFR attenuation reflects depression severity. (2) Both baseline NSFR index (AUC = 0.615) and COX-2 level (AUC = 0.725) independently predicted early treatment efficacy, with patients exhibiting lower baseline NSFR index or higher baseline COX-2 levels showing superior early efficacy. (3) The combined predictive model incorporating baseline NSFR index, COX-2, and PLA2 demonstrated optimal predictive performance (AUC = 0.786).
conclusionThis study confirms that greater NSFR attenuation is associated with more severe depressive symptoms. Baseline NSFR and COX-2 hold promise as potential predictive biomarkers. Furthermore, the combined model based on NSFR and inflammatory cytokines exhibits superior predictive value, providing a potential basis for optimizing individualized DD treatment strategies and exploring anti-inflammatory therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.